about
Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's diseaseSafety of lumbar puncture procedures in patients with Alzheimer's disease.Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis.Amyloid-β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAβACs.Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value.Fibrillar β-amyloid 1-42 alters cytokine secretion, cholinergic signalling and neuronal differentiation.Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.Biomarkers in Alzheimer's disease and lewy body disorders with dementia.Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor.Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease.Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia.Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.Discovery of novel choline acetyltransferase inhibitors using structure-based virtual screening.DMSO: A Mixed-Competitive Inhibitor of Human Acetylcholinesterase.PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase.Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease.Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment.Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.Unbiased expression mapping identifies a link between the complement and cholinergic systems in the rat central nervous system.Soluble Aβ42 Acts as Allosteric Activator of the Core Cholinergic Enzyme Choline AcetyltransferaseChanges in neuromuscular structure and functions of human colon during ageing are region-dependentProton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme-A plausible missing link for their association with incidence of dementia
P50
Q30497749-CC5B8885-BCC4-4061-9259-5AB582C58C3DQ33671485-AF054DBF-4CBE-4444-ABAF-A3B9581585E4Q33715239-3060DCC1-24C1-45F4-9A4A-BB989B8DD2B5Q33968308-A3F907F7-7CB7-4B75-8C72-CD08D641B774Q35250966-B631846A-B2EC-420C-9160-8AF4CB404DB1Q37104891-4F64E881-DB3D-4B58-A246-AC36409C2B79Q37658872-2A819634-9D27-4EDB-9662-2C8CD0A7C675Q38269427-F7FD6CDC-018B-4CD1-8DAE-DA09D023A841Q38967438-A284E73A-3BA6-4187-B161-24DD9CB0B94EQ39695636-17A70484-4FEB-4830-816A-8BEC926EBDA1Q41849805-925212AC-298D-427C-85F2-7799076E396FQ42464348-B5E2F50D-4FF3-41CB-8DED-7EB7A8B9FEA6Q42472858-3C21BCA2-02C0-465A-9BA9-4B6011C0D08BQ44792320-E5D24BAE-8E81-48BE-BF51-59310A7DBD6AQ44828253-982E349B-CE72-4C6C-85E8-CC3E0B2D2994Q46625223-A48EC3E5-E5F7-446D-B4A4-A14117C9D863Q46707194-1E727C7E-DD7C-4A88-AD45-568DD8DCE85AQ47111224-A254D44F-916A-48BC-B58D-6F68C9ECE36DQ48215101-352BFB5F-FAE7-475C-8DEE-03D68A730D64Q48231733-3F2816FF-58A6-4755-9BF8-07F79C25E84CQ48268462-F762F920-623F-4C3F-A87F-07A480E283FAQ48323376-82C2D86B-F871-483E-BB80-DF444BB8BC5DQ48420952-0D76F42C-267B-4F6F-B882-31692C24831BQ48473978-713C49BC-C749-4AD4-8D9F-AECCD9EC5FFAQ50546601-4D05CE09-6841-44C2-9824-03BC8440AEF4Q50705452-6B543843-1A71-4442-B81D-48960A9D03D1Q50726972-83AFC985-AE9B-4862-90AF-9BDB3CA6A98EQ51773023-4FC8A606-DC18-48F6-980D-5A489A23AC2CQ54419374-34959BF6-C815-435C-BE31-499241632DE9Q57110843-1FB7B991-BB77-493D-95DC-33ED2CC27CA4Q91517980-6CAE6D91-ED8F-4C5F-ACA9-3056F3A0E1EDQ94561625-C042911D-5534-42B2-953B-9DE6C32EEF41
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Taher Darreh-Shori
@ast
Taher Darreh-Shori
@en
Taher Darreh-Shori
@es
Taher Darreh-Shori
@nl
Taher Darreh-Shori
@sl
type
label
Taher Darreh-Shori
@ast
Taher Darreh-Shori
@en
Taher Darreh-Shori
@es
Taher Darreh-Shori
@nl
Taher Darreh-Shori
@sl
prefLabel
Taher Darreh-Shori
@ast
Taher Darreh-Shori
@en
Taher Darreh-Shori
@es
Taher Darreh-Shori
@nl
Taher Darreh-Shori
@sl
P106
P31
P496
0000-0003-1176-6258